Table 2.
Results
| Measure | N | Mean (SD) | P Value | |||
| Pre-TCZ | Post-TCZ | |||||
| Graft function | ||||||
| eGFR T0 versus T3m | 10 | 41.6 (18.8043) | 42.2 (17.6937) | 0.71 | ||
| eGFR T0 versus T6m | 10 | 41.6 (18.8043) | 39.2 (19.0193) | 0.43 | ||
| eGFR T0 versus T12m | 6 | 41.7 (20.2846) | 41 (26.6983) | 0.88 | ||
| Proteinuria T0 and Tc | 10 | 1.61 (1.1426) | 1.85 (2.3244) | 0.70 | ||
| Slope eGFR (T0−12 m versus T0+12 m) | 10 | −0.14 (0.9082) | −0.33 (1.0724) | 0.60 | ||
| Histology | ||||||
| MVI | 6 | 4.8333 (1.472) | 4.1667 (2.0412) | 0.39 | ||
| Total chronicity score | 6 | 4.3333 (1.9664) | 5.6667 (3.4448) | 0.29 | ||
| IFTA | 6 | 2.5 (0.8367) | 3.3333 (1.7512) | 0.38 | ||
| MMDx scores | ||||||
| AbMR | 5 | 0.792 (0.1681) | 0.776 (0.2615) | 0.86 | ||
| Total rejection | 5 | 0.83 (0.1454) | 0.79 (0.1488) | 0.51 | ||
| Atrophy fibrosis | 5 | 0.362 (0.2374) | 0.584 (0.1494) | 0.21 | ||
| Global disturbance | 5 | 0.884 (2.243) | 1.646 (1.2158) | 0.44 | ||
TCZ, tocilizumab; T0, at time of initiation of TCZ; T3m, 3 months after initiation of TCZ; Tc, at time of most recent followup; MVI, microvascular inflammation (glomerulitis plus peritubular capillaritis score); IFTA, interstitial fibrosis and tubular atrophy; MMDx, Molecular Microscope Diagnostic System; AbMR, antibody-mediated rejection.